Nuovo articolo sulla caratterizzazione di nanomedicine tramite DLS e AF4-UV-MALS. Applicazione su nanovaccino contro l'HIV

Alleghiamo una recente pubblicazione sulla caratterizzazione di un vaccino a base di nanoparticelle HIV tramite DLS e AF4. Questa ricerca è stata condotta da gruppi diversi in Francia e Spagna, che hanno utilizzato, tra gli altri strumenti, il VASCO2 e il WALLIS di Cordouan Technologies.

Un breve estratto dall'introduzione del paper: "Nanoformulations are complex systems where physicochemical properties determine their therapeutic efficacy and safety. In the case of nanovaccines, particle size and shape play a crucial role on the immune response generated. Furthermore, the antigen’s integrity is also a key aspect to control when producing a nanovaccine. The determination of allthose physicochemical properties is still an analytical challenge and the lack of well-established methods hinders the access of new therapeutics to the market. In this work, robust methods for the characterization of a novel HIV nanoparticle-based vaccine produced in good manufacturing practice (GMPs)-like environment were developed. With slightly polydisperse particles (< 0.2) close to 180 nm of size, batch-mode Dynamic Light Scattering (DLS) was validated to be used as a quality control technique in the pilot production plant.  [...]"